2Seventy Bio Inc. has announced a significant regulatory development concerning its common stock. The company plans to delist its shares from Nasdaq and will file a Certification and Notice of Termination of Registration on Form 15 with the U.S. Securities and Exchange Commission $(SEC.UK)$, seeking to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934. This move will also suspend 2Seventy Bio's reporting obligations under Sections 13 and 15(d) of the Exchange Act. The changes follow the company's acquisition by Bristol-Myers Squibb, which has resulted in 2Seventy Bio becoming a wholly-owned subsidiary.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.